Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PB432 in COVID-19 Inpatients with Acute Respiratory Insufficiency
2020-003779-17Phase 2Completed
- Sponsor
- Pohl-Boskamp
- Start
- Nov 2020
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) and acute respiratory decompensation comparing PB432 with Placebo (2 arms). Primary endpoint: SOSS-14 (sum of daily OSS scores from Day 2 to Day 15). Started Nov 2020; status: completed.
02
Drugs
ELOM-080
03
Conditions
coronavirus disease 2019 (COVID-19)acute respiratory decompensation
Beyond the preview
Go deeper on 2020-003779-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003779-17.